OCULAR THERAPEUTIX, INC Selling and Marketing Expense in USD from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
Summary
Ocular Therapeutix, Inc quarterly/annual Selling and Marketing Expense history and growth rate from 2012 to Q3 2025.
  • Ocular Therapeutix, Inc Selling and Marketing Expense for the quarter ending September 30, 2025 was $13.1M, a 23.8% increase year-over-year.
  • Ocular Therapeutix, Inc Selling and Marketing Expense for the twelve months ending September 30, 2025 was $51.8M, a 29.5% increase year-over-year.
  • Ocular Therapeutix, Inc annual Selling and Marketing Expense for 2024 was $41.6M, a 2.57% increase from 2023.
  • Ocular Therapeutix, Inc annual Selling and Marketing Expense for 2023 was $40.5M, a 1.57% increase from 2022.
  • Ocular Therapeutix, Inc annual Selling and Marketing Expense for 2022 was $39.9M, a 13.4% increase from 2021.
Selling and Marketing Expense, Trailing 12 Months (USD)
Selling and Marketing Expense, Quarterly (USD)
Selling and Marketing Expense, YoY Quarterly Growth (%)
Selling and Marketing Expense, Annual (USD)
Selling and Marketing Expense, YoY Annual Growth (%)

OCULAR THERAPEUTIX, INC Quarterly Selling and Marketing Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $51.8M $13.1M +$2.52M +23.8% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-04
Q2 2025 $49.3M $13.7M +$3.74M +37.4% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-05
Q1 2025 $45.6M $14.1M +$3.97M +38.9% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-05
Q4 2024 $41.6M $10.8M +$1.59M +17.2% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-03
Q3 2024 $40M $10.6M +$1.26M +13.5% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-04
Q2 2024 $38.7M $9.99M -$1.16M -10.4% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-05
Q1 2024 $39.9M $10.2M -$652K -6.02% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-05
Q4 2023 $40.5M $9.25M -$1.29M -12.2% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-03
Q3 2023 $41.8M $9.32M -$871K -8.55% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $42.7M $11.2M +$1.01M +9.99% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $41.7M $10.8M +$1.77M +19.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $39.9M $10.5M +$1.4M +15.3% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-03
Q3 2022 $38.5M $10.2M +$610K +6.37% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $37.9M $10.1M +$1.75M +20.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $36.2M $9.06M +$977K +12.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $35.2M $9.14M +$2.33M +34.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-11
Q3 2021 $32.9M $9.58M +$3.06M +46.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $29.8M $8.39M +$2.24M +36.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $27.6M $8.09M +$956K +13.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $26.6M $6.81M -$331K -4.64% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-06
Q3 2020 $26.9M $6.52M -$257K -3.79% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $27.2M $6.15M -$1.07M -14.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $28.3M $7.13M +$3.78M +113% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $24.5M $7.14M +$4.85M +212% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $19.6M $6.78M +$5.71M +535% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $13.9M $7.23M +$6.36M +733% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 $7.57M $3.35M +$2.63M +367% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $4.94M $2.29M +$1.39M +154% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 $3.55M $1.07M -$2.17M -67% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $5.73M $867K -$5.97M -87.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $11.7M $717K -$5.31M -88.1% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 $17M $903K -$1.62M -64.3% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-12
Q3 2017 $18.6M $3.24M +$1.94M +150% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $16.7M $6.83M +$5.34M +358% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $11.3M $6.03M +$4.64M +334% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $6.7M $2.53M +$1.38M +121% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-07
Q3 2016 $5.32M $1.29M +$496K +62.2% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $4.82M $1.49M +$451K +43.3% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 $4.37M $1.39M +$519K +59.7% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-05
Q4 2015 $3.85M $1.14M +$485K +73.7% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-08
Q3 2015 $3.37M $798K +$319K +66.6% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-09
Q2 2015 $3.05M $1.04M +$506K +94.6% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 $2.54M $870K +$560K +181% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 $1.98M $658K Oct 1, 2014 Dec 31, 2014 10-K 2017-03-10
Q3 2014 $479K +$331K +224% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-10
Q2 2014 $535K +$392K +274% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-10
Q1 2014 $310K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-15
Q3 2013 $148K Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-12
Q2 2013 $143K Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-29

OCULAR THERAPEUTIX, INC Annual Selling and Marketing Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $41.6M +$1.04M +2.57% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-03
2023 $40.5M +$627K +1.57% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-03
2022 $39.9M +$4.73M +13.4% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-03
2021 $35.2M +$8.58M +32.2% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-11
2020 $26.6M +$2.12M +8.67% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-06
2019 $24.5M +$19.5M +396% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $4.94M -$12.1M -70.9% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-12
2017 $17M +$10.3M +154% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 $6.7M +$2.85M +74% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-07
2015 $3.85M +$1.87M +94.3% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 $1.98M +$1.36M +217% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-10
2013 $625K -$32K -4.87% Jan 1, 2013 Dec 31, 2013 10-K 2016-03-10
2012 $657K Jan 1, 2012 Dec 31, 2012 10-K 2015-03-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.